Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

Phase 2 Terminated 43 enrolled Hoosier Cancer Research Network Eli Lilly and Company · collab Walther Cancer Institute · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients with relapsed or chemotherapy-refractory SCLC have a dismal prognosis. Unfortunately, available treatments result in few durable responses. Pemetrexed is a well-tolerated agent, which is active in NSCLC. Since chemotherapy agents, which are active in NSCLC, are usually also active in SCLC, this trial will examine the efficacy and activity of pemetrexed in this palliative setting

Timeline

Start: 2005-01
Primary completion: 2005-10
Completion: 2005-10

Outcome

Outcome not reported

Stopped: “The results from the interim analysis were not favorable to continue this trial.”

Publications

Results Jalal S, Ansari R, Govindan R, Bhatia S, Bruetman D, Fisher W, Masters G, White A, Stover D, Yu M, Hanna N; Hoosier Oncology Group. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol. 2009 Jan;4(1):93-6. doi: 10.1097/JTO.0b013e31818de1e6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Pemetrexed	Small molecule	500 mg/m2	Intravenous